NEBIVOLOL HYDROCHLORIDE | A203825 | HETERO LABS LTD UNIT III
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Forest Laboratories Inc. et al v. Torrent Pharmaceuticals Ltd. et al 1 patentANDA 203966, 203683, 203659, 203821, 203825nebivolol hydrochloride | D. Del. | 2012-03-13 | Terminated 2012-06-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.1839
per ea
Lowest NADAC/Unit
$0.1042
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 31722058830NEBIVOLOL 20 MG TABLET | $0.1839 | EA | Generic | — | 2026-06-17 |
| 31722058890NEBIVOLOL 20 MG TABLET | $0.1839 | EA | Generic | — | 2026-06-17 |
| 31722058730NEBIVOLOL 10 MG TABLET | $0.1474 | EA | Generic | — | 2026-06-17 |
| 31722058790NEBIVOLOL 10 MG TABLET | $0.1474 | EA | Generic | — | 2026-06-17 |
| 31722058530NEBIVOLOL 2.5 MG TABLET | $0.1217 | EA | Generic | — | 2026-06-17 |
| 31722058630NEBIVOLOL 5 MG TABLET | $0.1042 | EA | Generic | — | 2026-06-17 |
| 31722058690NEBIVOLOL 5 MG TABLET | $0.1042 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.